Brinton gets nod from DCGI for favipiravir in India

Pharma Company, Brinton Pharmaceuticals has received green signal from Drugs Controller General of India (DCGI) for marketing of favipiravir under the brand name faviton. The drug will be marketed in India and exported globally by the company and will be available in 200 mg tablets.

Favipiravir is an effective treatment option in the management of mild-to-moderate COVID-19 as per clinical evidence. The medicine is an orally-administered medication and more convenient compared to intravenously-administered medicines.

Rahul Kumar Darda, CMD, Brinton Pharmaceuticals, said, “We always wanted to launch “evidence-based cure” to combat COVID-19. Our strategic intent will be to improve the access through our strong distribution network that will help make faviton available across all COVID treatment centres and our MRP is Rs 59 per tablet”.

The drug will be available in a strip of 10 tablets and 50 tablets in a box.

  • Related Posts

    Illegal drug manufacturing racket busted in Baddi area

    In a major crackdown on the illegal drug trade, the Drugs Control Administration (DCA), Himachal Pradesh, on Friday busted a racket involved in the illicit manufacturing and storage of narcotic…

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    Hyderabad: The collaborative landscape of international pharmaceutical oversight reached a new milestone on May 5, 2026, as the Drugs Control Administration (DCA) of Telangana hosted the Second Regulatory Forum with…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Illegal drug manufacturing racket busted in Baddi area

    Illegal drug manufacturing racket busted in Baddi area

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Six Women Develop Serious Complications After C-Section

    Six Women Develop Serious Complications After C-Section

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

    Indian Pharma Majors Plan to Invest in US

    Indian Pharma Majors Plan to Invest in US